Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2015
July 2015, Vol 6, No 6
July 2015, Vol 6, No 6
MSKCC and ASCO Cancer Value Calculators
By
Jonathan B. Fassberg, MBA
VBCC Perspectives
,
Economics & Value
,
Value-Based Care
July 2015, Vol 6, No 6
There has been talk regarding pricing in healthcare for a number of years, so the recent move by the American Society of Clinical Oncology (ASCO) and by Memorial Sloan Kettering Cancer Center (MSKCC), discussed in this issue of
Value-Based Cancer Care
, is certainly a big deal, but is hardly surprising.
Read Article
Personalized Medicine Coalition Statement on ASCO’s New Conceptual Framework
By
Edward Abrahams, PhD
VBCC Perspectives
,
Economics & Value
,
Value-Based Care
July 2015, Vol 6, No 6
In the face of escalating costs of cancer drugs, the American Society of Clinical Oncology (ASCO) rightly asks, what is the value of these new medicines?
Read Article
Patient-Centric Cancer Care
By
Rick Lee
VBCC Perspectives
,
Economics & Value
,
Value-Based Care
July 2015, Vol 6, No 6
Rising to a level of equal status with cancer providers is a tall order for patients with cancer, yet it is precisely the intent of the Meaningful Use Stage 3 proposed standards that are set to take effect in 2018 (ie, patient-reported outcomes), as well as the value-based care initiatives. Providers need to drop their resistance and contemplate the following benefits of patient centricity.
Read Article
Oncology News - July 2015
Oncology News
July 2015, Vol 6, No 6
Read Article
The ASCO Value Framework: To What End?
ASCO’s Value Framework
,
Value-Based Care
,
VBCC Perspectives
,
Economics & Value
July 2015, Vol 6, No 6
Read Article
FDA News - July 2015
FDA Approvals, News & Updates
July 2015, Vol 6, No 6
The FDA’s Oncologic Drug Advisory Committee (ODAC) reviewed necitumumab (Eli Lilly & Co) for use in patients with metastatic squamous non–small-cell lung cancer (NSCLC). Necitumumab is an immunoglobulin G1 monoclonal antibody that inhibits the interaction between the human epidermal growth factor receptor (EGFR) and its ligands. EGFR expression is elevated in NSCLC and affects >95% of squamous NSCLC tumors.
Read Article
ASCO’s Value Framework Abandons the Hippocratic Oath
By
Robert Goldberg, PhD
ASCO’s Value Framework
,
Value-Based Care
,
VBCC Perspectives
,
Economics & Value
July 2015, Vol 6, No 6
The American Society of Clinical Oncology (ASCO) new value framework abandons the Hippocratic Oath. No longer is the doctor’s first obligation to “apply, for the benefit of the sick, all measures which are required.” Instead, ASCO’s value framework has the potential to help insurers “evaluate the relative value of new treatments” as they develop “benefit structures, adjustment of insurance premiums, and implementation of clinical pathways and administrative controls."
Read Article
ASCO Develops New Framework to Evaluate the Value of Cancer Therapies
By
Laura Morgan
ASCO’s Value Framework
July 2015, Vol 6, No 6
Cancer care is one of the fastest growing components of US healthcare costs and is estimated to reach $158 billion by 2020. The American Society of Clinical Oncology (ASCO) Value in Cancer Care Task Force attributes the rising cost of cancer care to several factors, including the overall aging of the population, the introduction of costly new drugs and innovative surgery and radiation techniques, and the adoption of more expensive diagnostic tests.
Read Article
Page 3 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma